44 stories mentioning ASX:CSLUpdated just now
Every FINWIRES story that references ASX:CSL, newest first.
Healthcare stocks advanced 1% at midday Monday.CSL (ASX:CSL) gained nearly 2% in recent trade.On the flip side, the materials sector struggled, shedding nearly 1%.BHP Group (ASX:BHP) shares fell past 1% in recent trade.
CSL's (ASX:CSL) CSL Seqirus unit disclosed publication of pivotal phase 3 study results for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) for influenza prevention in older adults in The Lancet Infectious Diseases, according to a Friday statement.The phase 3 randomized immunogenicity and safety study enrolled 7,699 adults aged 50 and older across eight countries and compared aQIVc with two enhanced influenza vaccines, demonstrating superiority versus the adjuvanted egg-based influenza vaccine comparator across all four influenza strains and age groups, and non-inferiority versus a recombinant influenza vaccine for three out of four strains in the 50-plus age group and four out of four strains in those aged 65 and older, the company said.The study also demonstrated immune responses that persisted throughout the influenza season and a well-tolerated safety profile, with most reactions mild or moderate and resolving within three days, CSL added.The study authors concluded that the findings support further evaluation of the vaccine and provide evidence for national immunization advisory groups considering enhanced influenza vaccination strategies for older adults, per the statement.The company's shares fell almost 1% in recent Friday trade.
Energy stocks advanced nearly 2% at midday Wednesday.Woodside Energy Group (ASX:WDS) gained more than 2% in recent trade.On the flip side, the healthcare sector struggled, shedding more than 1%.CSL (ASX:CSL) shares fell past 2% in recent trade.
CSL (ASX:CSL) said Vanguard Group raised its voting power in the firm to 7.001% as of Aug. 31 from 6% previously, according to a Friday Australian bourse filing.Vanguard holds 33.5 million ordinary shares in the firm as of Aug. 31, per the filing.
Australian shares were again flat with a negative bias as economic concerns mounted in the wake of renewed Middle East hostilities.The S&P/ASX 200 Index was little changed to close at 9,066.70.Brent crude oil futures climbed over $91 per barrel after the US and Iran conducted attacks in the Middle East.Overnight on Wall Street, the Dow Jones fell 0.7%, the S&P 500 0.3%, and the Nasdaq 0.1%.On the domestic front, Australia's manufacturing sector maintained modest growth in August, with stronger new orders, business confidence, and employment offset by softer production and renewed supply-chain and cost pressures, according to a survey by S&P Global.Australia's seasonally adjusted current account deficit widened to AU$27.22 billion in the June quarter from AU$25.45 billion in the previous quarter, data from the Australian Bureau of Statistics showed.Total dwelling approvals fell 3.6% to 17,687 in July in seasonally adjusted terms after rising 6.9% in June, according to a separate report from the statistics bureau.In company news, Collins Foods (ASX:CKF) said total company sales in the first 17 weeks of fiscal 2027 were up 6.6% on the prior corresponding period on a constant currency basis, with KFC total sales up 6.4% in Australia, down 2.5% in the Netherlands, and up 44% in Germany.WiseTech Global (ASX:WTC) appointed Jeff Howard as chief financial officer, effective Sept. 28.CSL (ASX:CSL) entered agreements with the US Administration to lower medicine costs and expand its manufacturing footprint in the US.
Australian shares are poised to fall on Tuesday as oil prices surged more than 2.5% after renewed US-Iran military action heightened concerns over global supply disruptions and a prolonged conflict.Overnight, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average fell 0.3%, 0.1%, and 0.7%, respectively.In the macroeconomy, Australia's manufacturing sector maintained modest growth in August, with stronger new orders, business confidence and employment offset by softer production and renewed supply-chain and cost pressures, according to a survey by S&P Global published Tuesday.Australia's home value index fell 0.9% in August, marking its fifth consecutive monthly decline and leaving national home values 3.6% below the March peak, as the housing downturn deepened through winter and declines spread across 93% of capital city suburbs, Cotality said in a Tuesday report.The ANZ-Roy Morgan Australian consumer confidence fell 2.6 points to 74.9 in the week of Aug. 24 to Aug. 30, ANZ reported Tuesday.In corporate news, Ausgold (ASX:AUC) reported Tuesday a fiscal 2026 loss of AU$0.0199 per share on revenue of AU$3 million, compared with a loss of AU$0.0307 on revenue of AU$1.6 million a year earlier.CSL (ASX:CSL) has entered agreements with the US Administration to lower medicine costs and expand its manufacturing footprint in the US.Australia's benchmark index fell 0.2%, or 16.3 points, to close at 9,076 on Monday.
CSL (ASX:CSL) has entered agreements with the US Administration to lower medicine costs and expand its manufacturing footprint in the US, according to a Tuesday Australian bourse filing.The company will provide Medicaid access to its medicines at prices comparable to those in other developed countries and extend similar pricing to newly launched therapies for all US payers under an agreement with the US Department of Health and Human Services, per the filing.The company has also entered into an onshoring agreement with the US Department of Commerce for its planned $1.5 billion expansion in Kankakee, Illinois, aimed at increasing production of plasma-derived therapies, the filing said.The company said the agreements are not expected to materially affect fiscal 2027 financial results, while providing greater certainty over US drug pricing and potential Section 232 tariff exposure, the filing added.
Healthcare stocks rose marginally at midday Thursday.CSL (ASX:CSL) inched up in recent trade.Meanwhile, the consumer staples sector struggled, shedding more than 2%.Woolworths Group (ASX:WOW) shares fell past 3% in recent trade.
Healthcare stocks advanced more than 1% at midday Tuesday.CSL (ASX:CSL) gained nearly 3% in recent trade.Meanwhile, the materials sector fell marginally.Woodside Energy Group (ASX:WDS) shares were down nearly 1% in recent trade after dropping its target to invest $5 billion in new energy products and lower-carbon services by 2030.
Healthcare stocks advanced nearly 2% at midday Wednesday.CSL (ASX:CSL) gained almost 4% in recent trade.On the flip side, the information technology sector struggled, shedding almost 5%.Wisetech Global (ASX:WTC) shares fell nearly 13% in recent trade.
Australian shares were flat on Tuesday as the ceasefire between the US and Iran expired.The S&P/ASX 200 Index was little changed to close at 9,070.Brent crude futures gained for a third consecutive day to around $91 per barrel as prospects for a near-term resolution seemed distant.Overnight on Wall Street, the S&P 500 and the Dow Jones indices both fell 0.5%, while the Nasdaq Composite declined 0.3% on soft US economic data.On the domestic front, the ANZ-Roy Morgan Australian Consumer Confidence rose 1.5 points to 76.5 in the week of Aug. 17 to 23, taking confidence to its highest level in 24 weeks, ANZ Research reported.The Westpac-Melbourne Institute Consumer Sentiment Index rose 6% to 88.9 in August from 83.9 in July.In company news, CSL (ASX:CSL) logged $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago. For the 12 months ended June 30, revenue was $15.8 billion versus $15.56 billion previously. Its shares rose over 18% on market close.BHP Group (ASX:BHP) logged $2.60 in underlying basic earnings per share for fiscal 2026, compared with $2.002 a year ago. For the 12 months ended June 30, revenue was $58.76 billion from $51.26 billion previously.Lastly, EQT Holdings (ASX:EQT) received an unsolicited, non-binding proposal from TPG Global to acquire all of the company's shares via a scheme of arrangement for AU$24.55 in cash per share, less any dividends declared or paid. Its shares closed up over 22%.
CSL (ASX:CSL) expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.The biotechnology firm attributed the results to "strong fundamentals" of the plasma industry and said momentum is building behind its newer therapy products.Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax."CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs," said Interim Chief Executive Officer Gordon Naylor.Jefferies, commenting on the company's Behring business, said productivity gains were insufficient to offset lower revenue against the division's high fixed-cost base as the segment's gross margin declined 70 basis points to 49.6%.
Healthcare stocks advanced nearly 8% at midday Tuesday.CSL (ASX:CSL) gained almost 18% in recent trade after logging $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago.On the flip side, the communication services sector struggled, shedding more than 1%.Telstra Group (ASX:TLS) shares fell nearly 2% in recent trade.
(Updates with the stock movement in the headline and last paragraph.)CSL (ASX:CSL) logged $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago, a Tuesday filing showed.Analysts polled by FactSet expected $6.27.For the 12 months ended June 30, revenue was $15.8 billion versus $15.56 billion previously, the Australia-listed biotechnology company added. Analysts surveyed by FactSet expected $15.38 billion.The company's board declared a final dividend of $1.62 per share, unchanged from a year earlier, payable Oct. 2 to shareholders of record as of Sept. 10.CSL said it expects fiscal 2027 revenue to be in line with fiscal 2026, and underlying net profit after tax growth of about 5%.The company's shares surged nearly 18% in recent Tuesday trade.
CSL's (ASX:CSL) fiscal 2026 results are in line, and it guided for fiscal 2027 net profit after tax (NPAT) growth of around 5%, Jefferies said in a Tuesday note.The firm's normalized fiscal 2026 net profit after tax and before amortization of $3.1 billion fell around 4% year-over-year and 2% in constant currency, compared with the brokerage's forecast of $3.09 billion.Its fiscal 2026 normalized earnings per share of $5.38 decreased around 3% on the year-ago period, compared with Jefferies' estimate of $5.76.Its fiscal 2027 revenue is expected by the firm to be in line with the prior year and underlying NPAT growth of around 5%, implying an underlying CSL fiscal 2027 NPAT of around $2.98 billion on a constant currency basis, compared with Jefferies' forecast of $2.8 billion on a non-constant currency basis.The investment firm assigned CSL a hold rating and a price target of AU$119 per share.
CSL (ASX:CSL) logged $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago, a Tuesday filing showed.Analysts polled by FactSet expected $6.27.For the 12 months ended June 30, revenue was $15.8 billion versus $15.56 billion previously, the Australia-listed biotechnology company added. Analysts surveyed by FactSet expected $15.38 billion.The company's board declared a final dividend of $1.62 per share, unchanged from a year earlier, payable Oct. 2 to shareholders of record as of Sept. 10.CSL said it expects fiscal 2027 revenue to be in line with fiscal 2026, and underlying net profit after tax growth of about 5%.
Healthcare stocks advanced more than 1% at midday Monday.CSL (ASX:CSL) gained 1% in recent trade.On the flip side, the financial sector struggled, shedding more than 2%.Commonwealth Bank of Australia (ASX:CBA) shares fell past 2% in recent trade.
Energy stocks advanced 1% at midday Friday.Woodside Energy Group (ASX:WDS) gained almost 1% in recent trade after agreeing to divest its 70% operated interest in the Calypso Project in Trinidad and Tobago to BP, which already holds the remaining 30% stake.On the flip side, the healthcare sector struggled, shedding 1%.CSL (ASX:CSL) shares fell marginally in recent trade after the European Commission revoked the marketing authorization for the Tavneos drug following a recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use.
CSL (ASX:CSL) and Vifor Fresenius Medical Care Renal Pharma said the European Commission revoked the marketing authorization for the Tavneos drug following a recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP), according to a Thursday statement.Tavneos was developed as a treatment for adults with the main forms of ANCA-associated vasculitis, a potentially life-threatening disease where the immune system mistakenly attacks the body's own blood vessels.The marketing authorization was revoked due to concerns related to data handling in a phase 3 trial before approval was granted, with the CHMP concluding that a positive benefit-risk balance for the drug could no longer be established."While we are disappointed by the decision, we respect the outcome of the regulatory process and are committed to implementing it in full," CSL and Vifor Fresenius said.Tavneos will no longer be available for prescribing in the European Union and European Economic Area countries.CSL's shares were down 1% in recent Friday trade.
Materials stocks advanced nearly 2% at midday Friday.BHP Group (ASX:BHP) gained almost 2% in recent trade even after reports that the miner is facing another strike from members of three unions in Western Australia's Pilbara region who have decided to impose a 24-hour ship-loading ban on Aug. 8 and will also down tools on Aug. 9.On the flip side, the healthcare sector struggled, shedding more than 2%.CSL (ASX:CSL) shares fell past 4% in recent trade.
Showing 1-20 of 44
